We are live on ! Find out more
WINT

Windtree Therapeutics
WINT

Delisted

WINT was delisted on the 20th of August, 2025.

Back to rankings

10 hedge funds and large institutions have $666K invested in Windtree Therapeutics in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

25% more funds holding

Funds holding: 8 → 10 (+2)

0% more ownership

Funds ownership: 0% → 0% (+0%)

62% less capital invested

Capital invested by funds: $1.76M → $666K (-$1.09M)

Holders
10
Holders Change
+2
Holders Change %
+25%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$88.4K
2
Millennium Management
Millennium Management
New York
+$59K
3
RWM
Rockwood Wealth Management
Pennsylvania
+$29.5K
4
TRCT
Tower Research Capital (TRC)
New York
+$29.5K
5
UBS Group
UBS Group
Switzerland
+$29.5K

Top Sellers

Rank Fund Capital Flow
1
KC
Kepos Capital
New York
-$188K
2
BlackRock
BlackRock
New York
-$56K
3
Federated Hermes
Federated Hermes
Pennsylvania
-$1K

WINT Hedge Fund Activity: Q2 2022 in Review

10 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Windtree Therapeutics (WINT) for Q2 2022, worth a combined $666K — down 62% from $1.76M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new WINT positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $88.4K. The largest seller was Kepos Capital, exiting entirely with an estimated $188K sold.

  • 10 institutional investors held Windtree Therapeutics (WINT) as of Q2 2022, up from 8 in Q1 2022.
  • Funds reported $666K of Windtree Therapeutics stock for Q2 2022, down 62% quarter-over-quarter.
  • 4 funds opened new Windtree Therapeutics positions in Q2 2022 and 2 closed out, a net change of +2 holders.
  • The largest Windtree Therapeutics buyer in Q2 2022 was Renaissance Technologies, an estimated $88.4K added.
  • The largest Windtree Therapeutics seller in Q2 2022 was Kepos Capital, an estimated $188K sold.

Based on aggregated 13F filings for Q2 2022.